| CAS NO: | 223134-72-3 |
| 包装 | 价格(元) |
| 500µg | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| Cas No. | 223134-72-3 |
| 别名 | SCH 13521-d7 |
| Canonical SMILES | FC(F)(C1=C(C=CC(NC(C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)=C1)[N+]([O-])=O)F |
| 分子式 | C11H4D7F3N2O3 |
| 分子量 | 283.3 |
| 溶解度 | Methanol: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Flutamide-d7is intended for use as an internal standard for the quantification of flutamide by GC- or LC-MS. Flutamide is an androgen receptor antagonist (Kis = 1.3 and 7.5 µM for the cytosolic rat ventral prostate and anterior pituitary receptors, respectively) and prodrug form of 2-hydroxy flutamide .1Flutamide is converted to 2-hydroxy flutamide by the cytochrome P450 (CYP) isoform CYP1A2 in human liver microsomes.1It is cytotoxic to PC3 and LNCaP prostate cancer cells with IC50values of 98.8 and 81.8 µM, respectively.2Flutamide (50 mg/kg per day) reduces tumor growth in a PC-82 mouse xenograft model.3Formulations containing flutamide have been used in the treatment of prostate cancer. 1.Shet, M.S., McPhaul, M., Fisher, C.W., et al.Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2Drug Metab. Dispos.25(11)1298-1303(1997) 2.Shi, Q., Wada, K., Ohkoshi, E., et al.Antitumor agents 290. Design, synthesis, and biological evaluation of new LNCaP and PC-3 cytotoxic curcumin analogs conjugated with anti-androgensBioorg. Med. Chem.20(13)4020-4031(2012) 3.Nnane, I.P., Long, B.J., Ling, Y.Z., et al.Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: An inhibitor of androgen synthesisBr. J. Cancer83(1)74-82(2000) |
m.cnreagent.com